Laura Perez
Psychiatric/Mental Health · Everett, WANPI 1023309135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 26.8% of the total. 2025 is the largest year on record at $2,209, more than ten times the $184 reported in 2021. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$427
- Neurocrine Biosciences, Inc.$314
- Teva Pharmaceuticals USA, Inc.$299
- Lundbeck LLC$260
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,86999%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,928 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 38 | $873 |
| Risperidone OdtRisperidone | 21 | $834 |
| Clonazepam | 95 | $795 |
| Trazodone Hcl | 35 | $535 |
| Quetiapine Fumarate | 29 | $490 |
| Methylphenidate ErMethylphenidate Hcl | 22 | $444 |
| Olanzapine | 20 | $397 |
| Bupropion XlBupropion Hcl | 26 | $379 |
| Methylphenidate Hcl | 24 | $349 |
| Lamotrigine | 29 | $281 |
| Risperidone | 22 | $261 |
| Escitalopram Oxalate | 24 | $232 |
| Fluoxetine Hcl | 13 | $226 |
| Divalproex Sodium | 17 | $216 |
| Duloxetine Hcl | 15 | $137 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Everett
- Angela KokinakosEverett$9K
- Hyesoon ChoiEverett$8K
- Sandra CarrierEverett$7K
- Jana RobisonEverett$5K
- Isabel Zaragoza-SanchezEverett$4K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
- Jennifer WilsonYakima$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.